LOC102724428 Drug Discovery Landscape & Assay Solutions

  • By admin
  • 13 Aug 2026
  • Comments

Emerging Target from the Dark Genome: High-Fidelity Reagents for De Novo Validation and Functional Annotation

TarMart Solution Ecosystem & Related Targets

Comprehensive reagent toolkit for LOC102724428 exploratory drug discovery. Select your validation modality below:

Component / Network Product Description Product Link
Antigen / Transcript LOC102724428 Recombinant Protein (Full-length, >95% purity, <1 EU/µg endotoxin, HEK293 or E. coli expressed) and Custom RNA / Expression Vector (Sequence Verified). View LOC102724428 Products
Gene Delivery LOC102724428 Promise-ORF / Lentivirus (Codon-optimized, Kozak consensus, full-length ORF for stable cell line construction). View LOC102724428 Products
Benchmark Ab / Probe Anti-LOC102724428 Recombinant mAb Baseline and Probe/PAb (Positive control generated against TarMart immunogen). View LOC102724428 Products
Validator LOC102724428 siRNA Set (3 unique targets, validated for knockdown verification and specificity checks). View LOC102724428 Products
Related Targets & Controls MALAT1 (lncRNA pathway marker), HOTAIR (chromatin remodeling partner), eGFP (expression control), Luciferase (binding normalization), β-Actin (ACTB, cytoskeleton marker), GAPDH (loading control). View MALAT1 Products / View HOTAIR Products / View eGFP Products / View Luciferase Products / View ACTB Products / View GAPDH Products

Critical Assay Challenges & The TarMart Advantage

Critical Assay Challenge The TarMart Advantage (Technical Spec)
Lack of Functional Annotation & Undefined Cellular Localization Sequence Verified ORF (100% NCBI RefSeq match, Mass Spectrometry confirmed); Multi-tag (His/Fc/SUMO/GST/MBP) recombinant proteins; Full-length lentivirus for native localization studies; theoretical MW and pI provided.
Absence of Commercial Antibodies & Positive Controls High-purity (>95%) recombinant immunogen (HEK293 expressed for native glycosylation) for custom antibody development; Benchmark recombinant mAb included.
False Positive Binding & RNAi Specificity Validated siRNA pool (3 unique targets) for knockdown confirmation; ORF rescue clones available for phenotypic rescue experiments; Sanger sequencing raw data provided.
Expression Solubility Issues & Delivery Barriers Multiple expression hosts (E. coli, HEK293) and tag options (His-SUMO, GST, MBP) with solubility-screened lysates; High-titer lentivirus particles with puromycin selection for rapid stable line generation.
Cross-species Orthology Uncertainty Human/Mouse/Rat ortholog comparison sequences provided; evolutionary conservation analysis for preclinical model selection.

Live LOC102724428 R&D Tracker

Market data changes daily. Access the latest global pipeline status directly:

Global Clinical Landscape & Future Outlook

LOC102724428 represents an uncharacterized locus in the dark genome, with no active clinical pipeline or established disease indication. The pharmaceutical industry is increasingly mining such loci for novel therapeutic opportunities, shifting focus from traditional protein targets to RNA-based modalities and sequence-specific interventions (ASOs, RNAi). The immediate priority is robust target validation using AI-driven structural prediction and CRISPR screens. As functional annotation emerges, the next wave of R&D will likely focus on biomarker association, structural elucidation, and foundational intellectual property generation. TarMart's sequence-verified reagents enable safe and reproducible exploration of this frontier.

Competitive Modality & Validation Snapshot

For uncharacterized loci, the primary R&D phase is Target Validation. Current approaches and corresponding assay needs:

Research Phase / Modality Representative Players Critical Assay Need (Why TarMart?)
Target ID & Validation (CRISPR/ORF/siRNA) Broad Institute, Sanger Institute, Academic Consortia Phenotypic rescue with ORF clones; Knockdown specificity with validated siRNA; Stable cell line generation with lentivirus.
Modality Discovery (ASO/RNAi) Early-stage Biotechs Knockdown validation (siRNA & vectors); Expression monitoring (reporter cell lines).
Structural Elucidation AlphaFold/ESMFold Prediction Groups High-purity recombinant protein for crystallization/X-ray validation; SPR/BLI-grade reagents.
Chemical Probing (TPD / Small Molecule) Targeted Protein Degradation Startups, Academic Consortia Cell-permeable expression systems; Stable cell lines for transcriptional regulation assays; PROTAC-compatible reagents.
Antibody Development (De Novo) Early-stage Biotech, CRO Partners High-purity immunogen (>95%, endotoxin-controlled) for custom rabbit monoclonal or polyclonal antibody generation.